tRNAArg (UCU)-1 Depletion Triggers SMARCC2 Loss and Neuroendocrine Transition in Prostate Cancer

The University of Chicago and Fred Hutchinson team performed high-resolution RNA sequencing on patient tumors, xenografts, and cell lines undergoing lineage plasticity. They observed consistent depletion of tRNAArg (UCU)-1 during the shift from androgen receptor-driven to neuroendocrine states, with functional experiments confirming that TARDBP and ZSCAN29 regulate its expression while tRNAArg (UCU)-1 controls SMARCC2 translation. Restoring either molecule reversed androgen receptor loss and resensitized cells to enzalutamide in vitro.

Original coverage emphasized the tRNA switch but underplayed how SMARCC2 disruption directly remodels chromatin accessibility at AR target loci, a mechanistic link that integrates this finding with prior epigenetic studies of neuroendocrine prostate cancer. Observational data from rapid autopsy cohorts show tRNAArg (UCU)-1 levels correlate with survival after AR pathway inhibitor failure, yet no prospective validation exists.

Therapeutic translation will require synthetic tRNA delivery systems or small molecules that stabilize tRNAArg (UCU)-1 without off-target effects on global translation. Preclinical safety and efficacy testing in neuroendocrine patient-derived xenografts is the immediate next step before any clinical candidate selection.